Table 2.
Baseline and outcome variables in the PP cohort by variant and treatment group.
| Generalised PP | Palmoplantar PP | ||||||
|---|---|---|---|---|---|---|---|
| Variable | IL23 (N = 9) | IL17 (N = 27) | p-Value | IL23 (N = 7) | IL17 (N = 16) | p-Value | |
| Sex | Male | 5 (56%) | 10 (37%) | 0.443 | 0 (0%) | 3 (19%) | 1 |
| Female | 4 (44%) | 17 (63%) | 3 (43%) | 13 (81%) | |||
| Height (cm%) | Median [Q1–Q3] | 162.50 [160.00–176.00] | 165.00 [160.00–172.00] | 0.882 | 160.00 [155.00–164.00] | 167.00 [160.00–170.00] | 0.082 |
| Weight (kg%) | Median [Q1–Q3] | 67.00 [58.00–78.50] | 79.00 [70.00–86.00] | 0.107 | 65.00 [63.00–73.00] | 71.50 [64.00–79.00] | 0.503 |
| Age at diagnosis | Median [Q1–Q3] | 32.00 [20.00–48.00] | 39.00 [20.00–52.00] | 0.597 | 45.00 [35.00–50.00] | 49.50 [39.00–55.00] | 0.3 |
| Education | Primary school | 0 (0%) | 2 (7%) | 0.747 | 0 (0%) | 0 (0%) | 0.499 |
| Middle school | 3 (33%) | 8 (30%) | 0 (0%) | 3 (19%) | |||
| High school | 2 (22%) | 1 (4%) | 1 (14%) | 1 (6%) | |||
| Higher education | 2 (22%) | 4 (15%) | 6 (86%) | 10 (63%) | |||
| Smoke | Never | 4 (44%) | 7 (26%) | 0.26 | 1 (14%) | 6 (38%) | 0.549 |
| Former | 2 (22%) | 14 (52%) | 3 (43%) | 4 (25%) | |||
| Current | 1 (11%) | 5 (19%) | 3 (43%) | 6 (38%) | |||
| PsA | Yes | 0 (0%) | 13 (48%) | 0.014 | 3 (43%) | 8 (50%) | 1 |
| No | 9 (100%) | 14 (52%) | 4 (57%) | 8 (50%) | |||
| Comorbidities | Yes | 3 (33%) | 18 (67%) | 0.122 | 5 (71%) | 9 (56%) | 0.657 |
| No | 6 (67%) | 9 (33%) | 2 (29%) | 7 (44%) | |||
| CV comorbidities | Yes | 2 (22%) | 14 (52%) | 0.654 | 2 (29%) | 6 (38%) | 0.546 |
| No | 3 (33%) | 12 (44%) | 1 (14%) | 10 (63%) | |||
| Diabetes | Yes | 1 (11%) | 4 (15%) | 0.999 | 1 (14%) | 0 (0%) | 0.2 |
| No | 5 (56%) | 22 (81%) | 3 (43%) | 16 (100%) | |||
| Naive Biologic | Yes | 7 (78%) | 14 (52%) | 0.262 | 1 (14%) | 10 (63%) | 0.069 |
| No | 2 (22%) | 12 (44%) | 6 (86%) | 6 (38%) | |||
| Obesity | Yes | 0 (0%) | 10 (37%) | 0.072 | 1 (14%) | 1 (6%) | 0.526 |
| No | 8 (89%) | 16 (59%) | 6 (86%) | 15 (94%) | |||
| Baseline DLQI | Median [Q1–Q3] | 25.50 [19.50–28.50] | 28.00 [26.00–30.00] | 0.292 | 28.00 [28.00–28.00] | 28.00 [25.00–30.00] | 0.868 |
| Baseline PASI | Median [Q1–Q3] | 12.00 [7.00–16.00] | 16.00 [12.00–20.00] | 0.057 | 7.00 [6.00–10.00] | 10.00 [8.00–15.50] | 0.119 |
| Previous therapies | Acitretin | 2 (22%) | 10 (37%) | 0.651 | 3 (43%) | 8 (50%) | 0.982 |
| Apremilast | 1 (11%) | 6 (22%) | 1 (14%) | 2 (13%) | |||
| Cyclosporine | 1 (11%) | 12 (44%) | 2 (29%) | 8 (50%) | |||
| MTX | 7 (78%) | 17 (63%) | 4 (57%) | 11 (69%) | |||
| Phototherapy | 1 (11%) | 4 (15%) | 0 (0%) | 1 (6%) | |||
| Oral steroids | 0 (0%) | 4 (15%) | 0 (0%) | 0 (0%) | |||
| Administered drug | Risankizumab | 5 (56%) | - | - | 3 (43%) | - | - |
| Guselkumab | 0 (0%) | - | 4 (57%) | - | |||
| Tildrakizumab | 4 (44%) | - | 0 (0%) | - | |||
| Secukinumab | - | 9 (33%) | - | 8 (50%) | |||
| Brodalumab | - | 11 (41%) | - | 3 (19%) | |||
| Ixekizumab | - | 7 (26%) | - | 5 (31%) | |||
| Is patient respondent? * | |||||||
| at week 12 | Yes | 4 (44%) | 22 (82%) | 0.162 | 1 (14%) | 8 (50%) | 0.338 |
| No | 4 (44%) | 5 (19%) | 4 (57%) | 8 (50%) | |||
| at week 24 | Yes | 2 (22%) | 23 (85%) | 0.119 | 2 (29%) | 9 (56%) | 0.326 |
| No | 2 (22%) | 3 (11%) | 3 (43%) | 4 (25%) | |||
| at week 48 | Yes | 4 (44%) | 17 (63%) | 1 | 1 (14%) | 10 (63%) | 1 |
| No | 1 (11%) | 5 (19%) | 0 (0%) | 1 (6%) | |||
| PASI 100 # | |||||||
| at week 12 | Yes | 1 (11%) | 15 (56%) | 0.022 | 0 (0%) | 2 (13%) | 0.533 |
| No | 8 (89%) | 11 (41%) | 7 (100%) | 12 (75%) | |||
| at week 24 | Yes | 6 (67%) | 11 (41%) | 0.225 | 1 (14%) | 6 (38%) | 0.354 |
| No | 2 (22%) | 14 (52%) | 5 (71%) | 8 (50%) | |||
| at week 48 | Yes | 4 (44%) | 13 (48%) | 0.673 | 0 (0%) | 7 (44%) | 0.417 |
| No | 2 (22%) | 11 (41%) | 1 (14%) | 4 (25%) | |||
| PASI 90 # | |||||||
| at week 12 | Yes | 2 (22%) | 19 (70%) | 0.019 | 1 (14%) | 4 (25%) | 1 |
| No | 7 (78%) | 8 (30%) | 6 (86%) | 12 (75%) | |||
| at week 24 | Yes | 5 (56%) | 17 (63%) | 1 | 2 (29%) | 6 (38%) | 1 |
| No | 3 (33%) | 9 (33.3%) | 4 (57%) | 8 (50%) | |||
| at week 48 | Yes | 5 (56%) | 16 (59%) | 0.637 | 1 (14%) | 8 (50%) | 1 |
| No | 1 (11%) | 8 (30%) | 0 (0%) | 3 (19%) | |||
| Switch | Yes | 0 (0%) | 5 (19%) | 0.302 | 2 (29%) | 3 (19%) | 0.621 |
| No | 9 (100%) | 22 (81%) | 5 (71%) | 13 (81%) | |||
| Discontinuation | Yes | 0 (0%) | 6 (22%) | 0.303 | 2 (29%) | 2 (13%) | 0.557 |
| No | 9 (100%) | 21 (78%) | 5 (71%) | 14 (88%) | |||
| Reason for discontinuation | Other | 0 (0%) | 3 (11%) | 2 (29%) | 0 (0%) | ||
| Collateral effect | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | |||
| Primary inefficacy | 0 (0%) | 0 (0%) | 0 (0%) | 1 (6%) | |||
| Loss of efficacy | 0 (0%) | 2 (7%) | 0 (0%) | 1 (6%) | |||
| Adverse events | 0 (0%) | 5 (19%) | 1 (14%) | 0 (0%) | |||
| Asthenia | 0 (0%) | 1 (4%) | 0 (0%) | 0 (0%) | |||
| Breast dermatitis | 0 (0%) | 0 (0%) | 1 (14%) | 0 (0%) | |||
| Pustulation on the back | 0 (0%) | 1 (4%) | 0 (0%) | 0 (0%) | |||
| Hand/foot pain after first administration | 0 (0%) | 1 (4%) | 0 (0%) | 0 (0%) | |||
| Increased hunger in the days following the injection | 0 (0%) | 1 (4%) | 0 (0%) | 0 (0%) | |||
| Injection site reaction | 0 (0%) | 1 (4%) | 0 (0%) | 0 (0%) | |||
| Drug survival | Median [Q1–Q3] | 52.00 [52.00–52.00] | 52.00 [52.00–52.00] | 0.129 | 52.00 [16.82–52.00] | 52.00 [52.00–52.00] | 0.479 |
PsA: psoriatic arthritis; IL-17: Interleukin-17; IL-23: Interleukin-23; CV: cardiovascular; DLQI = Dermatology Life Quality Index; MTX: Methotrexate; PASI = Psoriasis Area Severity Index; Q1: quartile 1; Q3: quartile 3; T1: week 12; T2: week 24; T3: week 48 * Patients considered responders if their IGA score was 0 or 1 or at least two points lower than at baseline # EP treatment responders were retrospectively defined as patients with a PASI90 or PASI100 response, an IGA score of 0–1, or a 2-point decrease from the baseline IGA score. PP treatment responders were those with a GPPASI90/PPPASI90 or GPPASI90/PPPASI100 response, a GPPGA/PPPGA score of 0–1, or a 2-point decrease from the baseline GPPGA/PPPGA score.